Clinical Trials Logo

Clinical Trial Summary

This is a prospective, single-center phase 1 clinical study aimed at determining the maximum-tolerated dose and safety of the combination of gemtuzumab ozogamicin (GO) and pracinostat (P) in patients with relapsed/refractory acute myeloid leukemia.


Clinical Trial Description

Relapsed/Refractory AML (RR-AML) is a serious medical condition where overall less than 10% survive beyond five years. Among RR-AML patients ineligible for intensive chemotherapy, this problem is magnified, and survival is measured in months. Hence, there is an urgent need for more efficacious and tolerable therapies for RR-AML. The majority of AML expresses the cluster of differentiation 33 (CD33) surface antigen. Gemtuzumab Ozogamicin (GO) is a recombinant, humanized anti-CD33 monoclonal antibody covalently attached to the cytotoxic antitumor antibiotic calicheamicin. GO binds to the CD33 antigen on AML cells forming a complex which is internalized, resulting in the intracellular delivery of calicheamicin. Calicheamicin then binds to DNA in the minor groove, inciting DNA double strand breaks and triggering cell death. GO was recently FDA approved for patients with AML who cannot tolerate intensive chemotherapy, and additionally received FDA approval in the RR-AML setting on the basis of a modest complete response (CR) rate of 26% [95% confidence interval (CI) 16-40%]. The investigators are studying whether the addition of the Histone deacetylase (HDAC) inhibitor pracinostat to GO is safe, and effective. HDACs plays important role in transcription regulation and in the pathogenesis of cancer. HDAC inhibitors induces histone hyperacetylation, resulting in an open chromatin structure and restore transcription of critically silenced genes. In AML, early clinical trials using single agent Pracinostat have demonstrated potential activity against the disease. In the context of GO, the investigators hypothesize HDAC inhibition may potentially synergize with GO to improve response against AML. Through HDAC inhibition mediated histone unwinding, open chromatin could allow for increased DNA delivery of calicheamicin within AML blasts and increased apoptosis. Further, pre-clinical data suggests HDAC inhibition could also increase CD33 expression in myeloid leukemia cells, thereby allowing for increased GO binding to AML blasts. This is the basis for the combination of these agents. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03848754
Study type Interventional
Source Medical College of Wisconsin
Contact
Status Completed
Phase Phase 1
Start date May 24, 2019
Completion date May 5, 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06141304 - Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT Phase 2
Active, not recruiting NCT05029141 - New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Not yet recruiting NCT06007911 - Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT04722952 - PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML Phase 3
Withdrawn NCT03932318 - Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients Phase 1/Phase 2
Recruiting NCT06307054 - CLL-1 CAR-NK Cells for Relapsed/Refractory AML Phase 1
Recruiting NCT04310592 - Natural Killer Cell (CYNK-001) Infusions in Adults With AML Phase 1
Recruiting NCT05237258 - Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia N/A
Active, not recruiting NCT04139434 - Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML Phase 1
Completed NCT05193448 - A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE
Recruiting NCT03867682 - Venetoclax and Lintuzumab-Ac225 in AML Patients Phase 1/Phase 2
Recruiting NCT06022003 - Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia Phase 2
Recruiting NCT03091933 - Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) Phase 1/Phase 2
Active, not recruiting NCT04330820 - Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) Phase 1/Phase 2
Recruiting NCT05305859 - Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML Phase 2
Approved for marketing NCT03245424 - Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation